Better Context Better Decisions

Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers without corporate access will find a wealth of contextualized life science insight ready to be purchased in the FENIX Marketplace. If our content sharing limitations are inconvenient for you, reach out to Brady for unlimited corporate, institutional, or individual access.

lilly cover image
$599
Posted in: Basal Insulin, Dual/triple agonist, GLP-1RA, Other Jul 01 | 2021Why Lilly Will Terminate GGG; Lilly ADA 2021 Investor UpdatePurchase Blast
news cover image
$599
Posted in: Basal Insulin, Bolus Insulin, GLP-1RA, Other, SGLT2i Jun 29 | 2021ADA 2021 Key Press Releases (June 29)Purchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, DPP-IVi, GLP-1RA, GLP-1RA + Basal, Glucose Monitoring, Insulin Delivery, SGLT2i Jun 28 | 2021ADA 2021 Key Press Releases (June 28)Purchase Blast
$599
Posted in: Basal Insulin, Dual/triple agonist, GLP-1RA, Glucose Monitoring, Other Jun 28 | 2021Novo Dual Agonist T2DM Intentions Disclosed at ADA Investor Event; Lilly Could Pursue Hypo Claim vs. Degludec in QW Basal Ph3Purchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery Jun 27 | 2021ADA 2021 Key Press Releases (June 27)Purchase Blast
novo cover image
$599
Posted in: GLP-1RA Jun 26 | 2021Wegovy Website AnalysisPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, SGLT2i Jun 25 | 2021ADA 2021 Key Press Releases (June 25)Purchase Blast
novo cover image
$599
Posted in: GLP-1RA Jun 08 | 2021Wegovy WAC Pricing AnalysisPurchase Blast
1 2 3 4 58

Get the Latest Analysis

Stay informed and aligned with frequent updates to keep a pulse on the industry.

If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact Brady.